Skip to content
Log in
Sponsored AI AM CLAUDE, A Beginner's Guide: Learn the basics of working with AI AI AM CLAUDE, A Beginner's Guide: Learn the basics of working with AI
Open access

Plasma inflammatory biomarker associations with Alzheimer's disease clinical stage and CSF biomarkers: evaluation of sex effects

Rene Coig Lavanya Jain M. Khrestian Elizabeth D. Tuason S. Rao Jagan A. Pillai J. Leverenz L. Bekris
Aug 2026 · medRxiv · 0 citations
Medicine

TL;DR

The findings identify a group of peripheral inflammatory markers associated with AD pathology and suggest that some of these relationships may vary by sex, warranting larger studies to clarify the role of sex in AD pathobiology.

DOI PubMed Semantic Scholar
Read PDF

Similar papers

Open access Jul 2026

Serum p-Tau217 and apolipoprotein E as potential biomarkers for Alzheimer's disease severity: a case-control study

Increased serum p-tau217 and decreased ApoE levels were significantly associated with greater AD severity, suggesting that both biomarkers may serve as complementary noninvasive indicators of disease severity in Alzheimer’s disease.

Ahmed Kadom Kalaf, Khawla A. Shemran, Waleed Azeez AlAmeedy · 0 citations
Open access Jul 2026

Association of target miRNAs expression in blood plasma and cerebrospinal fluid with Alzheimer's disease biomarkers level and cognitive decline.

The observed findings suggest that investigated miRNAs are not suitable for differentiation between different stages of cognitive impairment, however, miRNAs were associated with typical hallmarks of AD, which supports their important role in neurodegeneration.

David Vogrinc, M. Holcar, M. Lenassi et al. · 0 citations
Open access Aug 2026

Expression differences and diagnostic efficacy of core plasma biomarkers in Alzheimer’s disease, cerebral small vessel disease and healthy adults

Among patients with isolated AD or isolated CSVD, plasma p-Tau217 is the optimal specific biomarker for the diagnosis of AD and differentiation between AD and cerebral small vessel disease.

Xian-Dong Wang, Jun-Qiu Wu, Xuan Zhang et al. · 0 citations
Open access Jul 2026

Performance of Alzheimer Disease Plasma Biomarkers in Patients With Prion Diseases

This study provides Class II evidence that plasma NfL/p-tau217 discriminates patients with CJD from those with AD and Diagnosing AD with a single abnormal p-tau plasma biomarker risks misdiagnosing prion diseases as AD.

Thomas Coysh, Rhiannon Laban, Elena Veleva et al. · 0 citations
Review Open access Aug 2026

SELECTED BLOOD-BASED BIOMARKERS IN ALZHEIMER'S DISEASE: CLINICAL APPLICATIONS, DIAGNOSTIC UTILITY, AND IMPLEMENTATION CHALLENGES

Plasma biomarkers offer a transformative, non-invasive approach to early AD diagnosis and primary care triage, reducing reliance on CSF and PET scans and overcoming demographic and methodological limitations is essential for their widespread clinical adoption.

Małgorzata Witaszczyk, Alicja Sołtan, Natalia Wiktorzak et al. · 0 citations
Open access Jul 2026

CSF and plasma tau biomarkers in the Down syndrome–Alzheimer’s disease continuum

These findings highlight the complementary roles of CSF and plasma tau biomarkers in tracking disease progression: CSF biomarkers capture early pathological changes, whereas plasma biomarkers more effectively reflect disease progression within symptomatic stages.

J. Arranz, J. Lantero-Rodríguez, Luisa Sophie Braun-Wohlfahrt et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.